Is immunotherapy re-entering the kidney cancer arena from the back door? Considerations from the Phase I/II study of siltuximab

Immunotherapy

Volumn 3, Issue 4, 2011, Pages 487-490

  Porta, Camillo ^a,b   Pedrazzoli, Paolo ^a   Paglino, Chiara ^a,b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b Italian Nephro Oncology Group   (Italy)

Author keywords

IL 6; immunotherapy; kidney cancer; monocolonal antibodies; siltuximab

Indexed keywords

BEVACIZUMAB; INTERFERON; INTERLEUKIN 6; SILTUXIMAB;

CANCER IMMUNOTHERAPY; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; HUMAN; IMMUNOMODULATION; KIDNEY CARCINOMA; NOTE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL;

EID: 79953825469     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.11.19     Document Type: Note

References (18)

1. Enquist E, Zambiano N, Zbar B et al.: Molecular mechanisms of immune dysfunction in renal cell carcinoma. In:Renal Cell Carcinoma. Molecular Biology, Immunology and Clinical Management . Bukowski RM, Novick AC (Eds). Humana Press, Totowa, NJ, USA 63-78 (2000).
2. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T: Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev. (1), CD001425 (2005).
3. Demirer T, Barkholt L, Blaise D et al.: Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. Nat. Clin. Pract. Oncol. 5, 256-267 (2008).
4. Rosenberg SA, Yang JC, White DE, Steinberg SM: Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann. Surg. 228, 307-319 (1998).
5. McDermott DF, Ghebremichael MS, Signoretti S et al.: The high-dose aldesleukin (HD IL-2) 'SELECT' trial in patients with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 28(Suppl. 15) Abstract 4514 (2010).
6. Grepin R, Pagès G: Molecular mechanisms of resistance to tumor anti-angiogenic strategies. J. Oncol. DOI:10.1155/2010/835680 (2010).
7. Loges S, Schmidt T, Carmeliet P: Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer 1, 12-25 (2010).
8. + myeloid cells. Nat. Biotechnol. 25, 911-920 (2007).
9. Marigo L, Dolcetti L, Serafini P, Zanovello P, Bronte V: Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol. Rev. 222, 162-179 (2008).
10. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374, 1-20 (2003).
11. Kallen KJ: The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. Biochim. Biophys. Acta 1592, 323-343 (2002).
12. Blay JY, Negrier S, Combaret V et al.: Serum level of Interleukin-6 as a prognostic factor in metastatic renal cell carcinoma. Cancer Res. 52, 3317-3322 (1992).
13. Negrier S, Perol D, Menetrier-Caux C et al.: Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6 from the Groupe Francais d'Immunotherapie. J. Clin. Oncol. 22, 2371-2378 (2004).
14. Fumagalli L, Lissoni P, Di Felice G et al.: Pre-treatment serum markers and lymphocyte response to interleukin-2 therapy. Br. J. Cancer 80, 407-411 (1999).
15. Capuron L, Ravaud A, Gualde N et al.: Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinolgy 26, 797-808 (2001).
16. Rossi JF, Negrier S, James ND et al.: A Phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br. J. Cancer 103, 1154-1162 (2010).
17. Van Zaanen HC, Koopmans RP, Aarden LA et al.: Endogenous interleukin-6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL-6 antibodies indicates the existence of a positive feed-back loop. J. Clin. Invest. 98, 1441-1448 (1996).
18. Correale P, Cusi MG, Taglaferri P: Immunomodulatory properties of anticancer monoclonal antibodies: is the 'magic bullet' still a reliable paradigm? Immunotherapy 3, 1-4 (2011).